Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.

Mark G WardB WarnerN UnsworthS-W ChuahC BrownclarkeS ShiehM ParkesJ D SandersonZ ArkirJ ReynoldsP R GibsonP M Irving

Published in: Alimentary pharmacology & therapeutics (2017)

Infliximab drug levels are associated with the depth of response/remission in patients with Crohn's disease, but no such relationship was observed for adalimumab. More data are needed to explain the variation in drug levels.

Keyphrases

disease activity
rheumatoid arthritis
ulcerative colitis
juvenile idiopathic arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
adverse drug
drug induced
electronic health record
optical coherence tomography
big data
artificial intelligence